Abstract 2: First-phase ejection fraction is a powerful predictor of adverse events in asymptomatic patients with aortic stenosis and preserved total ejection fraction
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-0464
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Abstract 2: First-phase ejection fraction is a powerful predictor of adverse events in asymptomatic patients with aortic stenosis and preserved total ejection fraction ; volume:7 ; number:4 ; day:1 ; month:12 ; year:2020 ; pages:M7-M8 ; date:12.2020
Echo Research and Practice ; 7, Heft 4 (1.12.2020), M7-M8, 12.2020
- Urheber
-
Gu, H.
Saeed, S.
Boguslavskyi, A.
Carr-White, G.
Chambers, J.
Chowienczyk, P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/BF03651754
- URN
-
urn:nbn:de:101:1-2022061719455294409828
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gu, H.
- Saeed, S.
- Boguslavskyi, A.
- Carr-White, G.
- Chambers, J.
- Chowienczyk, P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Right ventricular ejection fraction
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction
Gender-related differences in heart failure with preserved ejection fraction
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Right ventricular ejection fraction
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction
Gender-related differences in heart failure with preserved ejection fraction
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Right ventricular ejection fraction
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction
Gender-related differences in heart failure with preserved ejection fraction
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment